Masimo Announces Full Market Release of rainbow Acoustic Monitoring Sensor RAS-45
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170928005381/en/
RAM noninvasively and continuously measures respiration rate using an innovative adhesive sensor with an integrated acoustic transducer, such as Masimo’s RAS-125c and now RAS-45, that is applied to the patient’s neck area. Using acoustic signal processing that leverages Masimo Signal Extraction Technology (SET®), the respiratory signal is separated and processed to display continuous respiration rate (RRa®) and respiratory waveform, with the option to listen to the sound of breathing from the acoustic sensor.
RRa has been shown to be accurate1,2, easy-to-use1, easy-to-tolerate1,3, and reliable1, and has also been shown to enhance patient compliance with respiration monitoring. In a study comparing pediatric patient tolerance of sidestream capnography with a nasal cannula to respiration rate monitoring with an RAS-125c acoustic sensor, 15 out of 40 patients removed the cannula, while only one removed the acoustic sensor.3 In a study of 98 patients consciously sedated during upper gastrointestinal endoscopy, researchers found that RRa monitoring with the RAS-125c sensor more accurately assessed respiration rate than capnography using end-tidal carbon dioxide (EtCO2) measurement or impedance pneumography.2 RAS-45 maintains the same performance parameters, range, and accuracy specification as RAS-125c.
With its smaller size, RAS-45 is well suited for monitoring pediatric patients and patients with shorter necks. The RAS-45 adhesive is transparent, lighter, and more flexible than the RAS-125c adhesive. Like RAS-125c, RAS-45 operates with Masimo MX technology boards to measure RRa, display the acoustic respiration wave form, and optionally allow clinicians to listen to the sound of breathing. Both sensors are for adult and pediatric patients who weigh more than 10 kg.
Continuous monitoring of respiration rate can be helpful in cases such
as sedation-based procedures and post-surgical patients receiving
patient-controlled analgesia for pain management.
@MasimoInnovates | #Masimo
- Macknet MR et al. Accuracy and Tolerance of a Novel Bioacoustic Respiratory Sensor in Pediatric Patients Anesthesiology. 2007;107:A84 (abstract).
- Goudra BG et al. Comparison of Acoustic Respiration Rate, Impedance Pneumography and Capnometry Monitors for Respiration Rate Accuracy and Apnea Detection during GI Endoscopy Anesthesia. Open J Anesthesiol. 2013;3:74-79.
Patino M et al. Accuracy of Acoustic Respiration Rate Monitoring in
Pediatric Patients. Paediatr Anaesth. 2013
- Stoelting, RK et al. APSF newsletter. 2011. www.apsf.org.
The Joint Commission Sentinel Event Alert. Issue 49,
August 8, 2012. www.jointcomission.org.
ORi has not received
*The use of the trademark Patient SafetyNet is under license from
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338.
- Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
- Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation.
The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
Masimodata on file.
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo RAS-45, RAM™, and RRa®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that
Evan Lamb, 949-396-3376